Niowave Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
smdailyjournal.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from smdailyjournal.com Daily Mail and Mail on Sunday newspapers.

United statesLuke nordquistAmanda crayDmitri bobilevNiowave incFusion pharmaceuticalsDrug administrationFusion pharmaceuticals incInvestor relations corporate communicationsExchange commissionChief medical officer dmitri bobilevChief executiveGood manufacturing practicePrivate securities litigation reform actInvestor relations

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer

Fusion Pharmaceuticals Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesDmitri bobilevAmanda crayLuke nordquistInvestor relations corporate communicationsFusion pharmaceuticalsDrug administrationFusion pharmaceuticals incExchange commissionNiowave incChief medical officer dmitri bobilevChief executiveGood manufacturing practicePrivate securities litigation reform actInvestor relations

Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy

Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMohit rawatAmanda crayEuropean commissionInvestor relations corporate communicationsNiowave incResearch centreFusion pharmaceuticals incPrnewswire fusion pharmaceuticals incFusion pharmaceuticalsExchange commissionDrug administrationHeidelberg universityJoint research centreUnited states patentChief business officer

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

HAMILTON, ON and BOSTON, Feb. 6, 2024 /CNW/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the

United statesAmanda crayNiowave incFusion pharmaceuticals incInvestor relations corporate communicationsFusion pharmaceuticalsCompany board of directorsNasdaq listing ruleResponse inhibitorsGood manufacturing practiceSenior directorInvestor relationsCorporate communications

Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesAmanda crayJohn valliantPrnewswire fusion pharmaceuticals incInvestor relations corporate communicationsHealthcare life sciences conferenceNiowave incFusion pharmaceuticalsAnnual healthcare life sciences conferenceChief executive officerResponse inhibitorsGood manufacturing practiceInvestor relations